Literature DB >> 30068653

HIV-1 Employs Multiple Mechanisms To Resist Cas9/Single Guide RNA Targeting the Viral Primer Binding Site.

Zhen Wang1,2, Wenzhou Wang1,3, Ya Cheng Cui2, Qinghua Pan1, Weijun Zhu4, Patrick Gendron5, Fei Guo4, Shan Cen6, Michael Witcher1,7, Chen Liang8,2,3.   

Abstract

The clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated protein 9 (Cas9) gene-editing technology has been used to inactivate viral DNA as a new strategy to eliminate chronic viral infections, including HIV-1. This utility of CRISPR-Cas9 is challenged by the high heterogeneity of HIV-1 sequences, which requires the design of the single guide RNA (sgRNA; utilized by the CRISPR-Cas9 system to recognize the target DNA) to match a specific HIV-1 strain in an HIV patient. One solution to this challenge is to target the viral primer binding site (PBS), which HIV-1 copies from cellular tRNA3 Lys in each round of reverse transcription and is thus conserved in almost all HIV-1 strains. In this study, we demonstrate that PBS-targeting sgRNA directs Cas9 to cleave the PBS DNA, which evokes deletions or insertions (indels) and strongly diminishes the production of infectious HIV-1. While HIV-1 escapes from PBS-targeting Cas9/sgRNA, unique resistance mechanisms are observed that are dependent on whether the plus or the minus strand of the PBS DNA is bound by sgRNA. Characterization of these viral escape mechanisms will inform future engineering of Cas9 variants that can more potently and persistently inhibit HIV-1 infection.IMPORTANCE The results of this study demonstrate that the gene-editing complex Cas9/sgRNA can be programmed to target and cleave HIV-1 PBS DNA, and thus, inhibit HIV-1 infection. Given that almost all HIV-1 strains have the same PBS, which is copied from the cellular tRNA3 Lys during reverse transcription, PBS-targeting sgRNA can be used to inactivate HIV-1 DNA of different strains. We also discovered that HIV-1 uses different mechanisms to resist Cas9/sgRNAs, depending on whether they target the plus or the minus strand of PBS DNA. These findings allow us to predict that a Cas9 variant that uses the CCA sequence as the protospacer adjacent motif (PAM) should more strongly and persistently suppress HIV-1 replication. Together, these data have identified the PBS as the target DNA of Cas9/sgRNA and have predicted how to improve Cas9/sgRNA to achieve more efficient and sustainable suppression of HIV-1 infection, therefore improving the capacity of Cas9/sgRNA in curing HIV-1 infection.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  CRISPR-Cas9; human immunodeficiency virus; primer binding site

Mesh:

Substances:

Year:  2018        PMID: 30068653      PMCID: PMC6158435          DOI: 10.1128/JVI.01135-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity.

Authors:  C Liang; X Li; L Rong; P Inouye; Y Quan; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures.

Authors:  Gang Wang; Na Zhao; Ben Berkhout; Atze T Das
Journal:  Cell Rep       Date:  2016-12-13       Impact factor: 9.423

3.  Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study.

Authors:  R Kaminski; R Bella; C Yin; J Otte; P Ferrante; H E Gendelman; H Li; R Booze; J Gordon; W Hu; K Khalili
Journal:  Gene Ther       Date:  2016-08       Impact factor: 5.250

4.  Initiation of HIV-1 reverse transcription is regulated by a primer activation signal.

Authors:  N Beerens; F Groot; B Berkhout
Journal:  J Biol Chem       Date:  2001-05-30       Impact factor: 5.157

5.  Human immunodeficiency virus type 1 can use different tRNAs as primers for reverse transcription but selectively maintains a primer binding site complementary to tRNA(3Lys).

Authors:  J K Wakefield; A G Wolf; C D Morrow
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

6.  Genetic engineering of human pluripotent cells using TALE nucleases.

Authors:  Dirk Hockemeyer; Haoyi Wang; Samira Kiani; Christine S Lai; Qing Gao; John P Cassady; Gregory J Cost; Lei Zhang; Yolanda Santiago; Jeffrey C Miller; Bryan Zeitler; Jennifer M Cherone; Xiangdong Meng; Sarah J Hinkley; Edward J Rebar; Philip D Gregory; Fyodor D Urnov; Rudolf Jaenisch
Journal:  Nat Biotechnol       Date:  2011-07-07       Impact factor: 54.908

7.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo.

Authors:  Su-Ru Lin; Hung-Chih Yang; Yi-Ting Kuo; Chun-Jen Liu; Ta-Yu Yang; Ku-Chun Sung; You-Yu Lin; Hurng-Yi Wang; Chih-Chiang Wang; Yueh-Chi Shen; Fang-Yi Wu; Jia-Horng Kao; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-19       Impact factor: 10.183

8.  Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing.

Authors:  Rafal Kaminski; Yilan Chen; Tracy Fischer; Ellen Tedaldi; Alessandro Napoli; Yonggang Zhang; Jonathan Karn; Wenhui Hu; Kamel Khalili
Journal:  Sci Rep       Date:  2016-03-04       Impact factor: 4.379

9.  CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape.

Authors:  Gang Wang; Na Zhao; Ben Berkhout; Atze T Das
Journal:  Mol Ther       Date:  2016-01-22       Impact factor: 11.454

10.  Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.

Authors:  Johnny H Hu; Shannon M Miller; Maarten H Geurts; Weixin Tang; Liwei Chen; Ning Sun; Christina M Zeina; Xue Gao; Holly A Rees; Zhi Lin; David R Liu
Journal:  Nature       Date:  2018-02-28       Impact factor: 49.962

View more
  15 in total

1.  Type III CRISPR-based RNA editing for programmable control of SARS-CoV-2 and human coronaviruses.

Authors:  Ping Lin; Guanwang Shen; Kai Guo; Shugang Qin; Qinqin Pu; Zhihan Wang; Pan Gao; Zhenwei Xia; Nadeem Khan; Jianxin Jiang; Qingyou Xia; Min Wu
Journal:  Nucleic Acids Res       Date:  2022-05-06       Impact factor: 19.160

Review 2.  Pathways Toward a Functional HIV-1 Cure: Balancing Promise and Perils of CRISPR Therapy.

Authors:  Jonathan Herskovitz; Mahmudul Hasan; Milankumar Patel; Bhavesh D Kevadiya; Howard E Gendelman
Journal:  Methods Mol Biol       Date:  2022

Review 3.  HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies.

Authors:  Edward F Kreider; Katharine J Bar
Journal:  Curr HIV/AIDS Rep       Date:  2022-04-11       Impact factor: 5.495

Review 4.  Challenges and Promise of Human Immunodeficiency Virus Remission.

Authors:  Yijia Li; Abbas Mohammadi; Jonathan Z Li
Journal:  J Infect Dis       Date:  2021-02-15       Impact factor: 5.226

Review 5.  Engineering CAR T Cells to Target the HIV Reservoir.

Authors:  Wenli Mu; Mayra A Carrillo; Scott G Kitchen
Journal:  Front Cell Infect Microbiol       Date:  2020-08-13       Impact factor: 5.293

Review 6.  Elimination of infectious HIV DNA by CRISPR-Cas9.

Authors:  Atze T Das; Caroline S Binda; Ben Berkhout
Journal:  Curr Opin Virol       Date:  2019-08-23       Impact factor: 7.090

Review 7.  Endogenous Retroviruses Walk a Fine Line between Priming and Silencing.

Authors:  Harrison Cullen; Andrea J Schorn
Journal:  Viruses       Date:  2020-07-23       Impact factor: 5.048

8.  Safe CRISPR-Cas9 Inhibition of HIV-1 with High Specificity and Broad-Spectrum Activity by Targeting LTR NF-κB Binding Sites.

Authors:  Cheng-Han Chung; Alexander G Allen; Andrew J Atkins; Neil T Sullivan; Greg Homan; Robert Costello; Rebekah Madrid; Michael R Nonnemacher; Will Dampier; Brian Wigdahl
Journal:  Mol Ther Nucleic Acids       Date:  2020-07-15       Impact factor: 8.886

9.  CRISPR-Cas9 Dual-gRNA Attack Causes Mutation, Excision and Inversion of the HIV-1 Proviral DNA.

Authors:  Caroline S Binda; Bep Klaver; Ben Berkhout; Atze T Das
Journal:  Viruses       Date:  2020-03-18       Impact factor: 5.048

10.  Multiplexed tat-Targeting CRISPR-Cas9 Protects T Cells from Acute HIV-1 Infection with Inhibition of Viral Escape.

Authors:  Youdiil Ophinni; Sayaka Miki; Yoshitake Hayashi; Masanori Kameoka
Journal:  Viruses       Date:  2020-10-28       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.